本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Kailera Therapeutics, Inc.

16.54
-0.6300-3.67%
盤後16.540.00000.00%19:30 EDT
成交量:54.95萬
成交額:914.75萬
市值:21.43億
市盈率:-7.34
高:17.16
開:17.14
低:16.37
收:17.17
52周最高:28.23
52周最低:16.37
股本:1.30億
流通股本:4,492.19萬
量比:0.55
換手率:1.22%
股息:- -
股息率:- -
每股收益(TTM):-2.2543
每股收益(LYR):-7,819.9811
淨資產收益率:-36.90%
總資產收益率:-22.73%
市淨率:1.92
市盈率(LYR):0.00

資料載入中...

公司資料

公司名字:
Kailera Therapeutics, Inc.
交易所:
NASDAQ
成立時間:
2024
員工人數:
- -
公司地址:
180 Third Avenue,4th Floor,Waltham,Massachusetts,United States
郵編:
02451
電話:
傳真:
- -
簡介:
Kailera Therapeutics, Inc.於2024年5月8日根據特拉華州法律註冊成立。該公司是一家處於臨床階段的生物技術公司,致力於通過推進多元化的研發管線,引領肥胖症治療的新時代。目前,該公司正在快速推進四款處於臨床階段的候選產品,這些產品利用多種基於胰高血糖素樣肽-1 (GLP-1) 的作用機制和給藥途徑。

董事

名稱
職位
John F. Milligan
Chairman and Director
Ronald C. Renaud, Jr.
Chief Executive Officer,Director and President
Adam Koppel
Independent Director
Andrew Kaplan
Independent Director
Christopher Hite
Independent Director
Frank Clyburn, Jr.
Independent Director
Martin Mackay
Independent Director
Michael Gladstone
Independent Director
Yuting Liu
Independent Director

股東

名稱
職位
Ronald C. Renaud, Jr.
Chief Executive Officer,Director and President
Paul Burgess
Chief Business Officer and Chief Operating Officer
Douglas Pagán
Chief Financial Officer
Jamie Coleman
Chief Commercial Officer
Paula Cloghessy
Chief People Officer
Scott Akamine
Chief Legal Officer and Secretary
Scott Wasserman
Chief Medical Officer